Adaptimmune Therapeutics plc

Adaptimmune Therapeutics plc is a risky bet given it's low Altman Z-score. Companies with a low Altman Z-score have a higher chance of going bankrupt within the next 2 years. The momentum for this stock is not very good. Adaptimmune Therapeutics plc has good growth characteristics. Adaptimmune Therapeutics plc is not very popular among insiders. Adaptimmune Therapeutics plc is a mediocre stock to choose.
Log in to see more information.
Adaptimmune Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the dev...
ADAP Fundamental Data by TradingView

News

Adaptimmune Therapeutics (NASDAQ:ADAP shareholders incur further losses as stock declines 11% this week, taking three-year losses to 80%
Adaptimmune Therapeutics (NASDAQ:ADAP shareholders incur further losses as stock declines 11% this week, taking three-year losses to 80%

Simply Wall St Every investor on earth makes bad calls sometimes. But you have a problem if you face massive losses more than once in...\n more…

Comparing Adaptimmune Therapeutics (NASDAQ:ADAP) & Gilead Sciences (NASDAQ:GILD)
Comparing Adaptimmune Therapeutics (NASDAQ:ADAP) & Gilead Sciences (NASDAQ:GILD)

Ticker Report Adaptimmune Therapeutics (NASDAQ:ADAP - Get Free Report) and Gilead Sciences (NASDAQ:GILD - Get Free Report) are both medical companies, but which is the better investment? We will compare the two...\n more…

Adaptimmune to Participate in Two Bank Conferences this September
Adaptimmune to Participate in Two Bank Conferences this September

Newsfile Corp. - News Releases Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - August 28, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor...\n more…

Adaptimmune Therapeutics (NASDAQ:ADAP) Shares Cross Above 50-Day Moving Average of $1.10
Adaptimmune Therapeutics (NASDAQ:ADAP) Shares Cross Above 50-Day Moving Average of $1.10

Ticker Report Adaptimmune Therapeutics plc (NASDAQ:ADAP - Get Free Report)'s stock price passed above its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $1.10 and...\n more…

Adaptimmune Therapeutics plc (NASDAQ:ADAP) Short Interest Up 13.2% in July
Adaptimmune Therapeutics plc (NASDAQ:ADAP) Short Interest Up 13.2% in July

Zolmax Adaptimmune Therapeutics plc (NASDAQ:ADAP - Get Free Report) was the recipient of a significant increase in short interest during the month of July. As of July 31st, there was short interest...\n more…

Q3 2024 EPS Estimates for Adaptimmune Therapeutics plc Reduced by HC Wainwright (NASDAQ:ADAP)
Q3 2024 EPS Estimates for Adaptimmune Therapeutics plc Reduced by HC Wainwright (NASDAQ:ADAP)

Ticker Report Adaptimmune Therapeutics plc (NASDAQ:ADAP - Free Report) - Investment analysts at HC Wainwright lowered their Q3 2024 earnings estimates for shares of Adaptimmune Therapeutics in a research report...\n more…